Hidradenitis Suppurativa

A new global study reveals hidradenitis suppurativa affects 1 in every 100 people, highlighting the need for increased awareness and improved health care strategies.

At a Dermatology Times Case-Based Roundtable event, Joe Gorelick, MSN, FNP-C, reviewed real-world strategies for hidradenitis suppurativa, highlighting growing preference for bimekizumab based on its dual IL-17A/IL-17F inhibition.

Navigator Medicines advances NAV-240, a promising bispecific antibody for HS, targeting dual pathways for enhanced treatment efficacy.

Participants agreed that HS is rarely controlled with monotherapy and often requires coordinated multimodal care.

Discover the potential of INF904, a groundbreaking oral therapy targeting C5aR for hidradenitis suppurativa and chronic spontaneous urticaria, promising new treatment options.

Discover the latest insights on hidradenitis suppurativa treatment, emerging therapies, and the importance of compassionate care for patients.

At Elevate-Derm, Buchi Neita, PA-C, discussed treatment expectations for vitiligo, triple-combination cream for acne, early diagnosis in HS, and what she’s looking forward to in the 2026 pipeline.

Karan Lal, DO, explores the transformative role of GLP-1 therapies in dermatology, highlighting their potential in treating inflammatory skin diseases and enhancing aesthetic care.

The topline data support advancing INF904 into larger, controlled trials as a potential convenient alternative to injectable biologics.

At the 10th Annual Symposium on Hidradenitis Suppurativa Advances, Ralph George, MD, FRCS, emphasized that the growing collaboration between medical and surgical management is redefining the role of procedures in HS.

Incyte launches Ingenuity Awards to empower HS community, funding innovative patient-driven initiatives for better treatment and outcomes in hidradenitis suppurativa.

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.

Avalo Therapeutics completes enrollment in the LOTUS trial for AVTX-009, targeting hidradenitis suppurativa with promising IL-1β inhibition.

According to a poster at Fall Clinical 2025, over 80% of patients remained flare-free across the 2-year period.

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

CO₂ laser treatment significantly enhances quality of life for hidradenitis suppurativa patients, showing promising outcomes in a large prospective study.

Emerging biologic combinations may open a new therapeutic frontier for severe hidradenitis suppurativa (HS) that fails to respond to conventional and single-pathway biologics.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa (HS), offering hope for effective treatment options at EADV Congress 2025.

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

Research shows it can take 7 to 10 years for individuals with HS to receive an accurate diagnosis.